Current Landscape of SCS Research Studies
Current Clinical Trials on Spinal Cord Stimulation for Chronic Pain
A patient living with chronic pain might enroll in a Spinal cord stimulation clinical trial to access an experimental therapy not yet widely available. These trials test how precisely targeted electrical pulses delivered to the spinal cord can interrupt pain signals before they reach the brain. The goal is to determine if this approach safely provides meaningful relief where other treatments have failed. Participants receive close medical monitoring to assess both the benefits and any potential side effects of the investigational device.
Current Landscape of SCS Research Studies
The current landscape of SCS research studies is defined by a decisive shift toward patient-specific, spinal cord stimulation clinical trials. Instead of broad efficacy studies, ongoing trials now rigorously compare novel waveforms, such as closed-loop and high-frequency stimulation, against traditional tonic stimulation. A central focus is identifying which patient phenotypes, including those with failed back surgery syndrome or painful diabetic neuropathy, achieve lasting relief from specific SCS parameters. Recent trials are also utilizing objective biomarkers, like quantitative sensory testing, to predict trial success before implantation, moving beyond subjective pain scores. This evolution is refining clinical protocols, ensuring that current SCS research studies deliver actionable data on maximizing long-term functional outcomes for each individual.
Key FDA-Designated Breakthrough Trials
Current SCS research is zeroing in on key FDA-designated breakthrough trials, which fast-track therapies for unmet pain needs. For example, a trial testing closed-loop stimulation targets real-time spinal cord response, aiming to reduce paresthesia-free pain relief. Another explores high-frequency waveforms to treat chronic back pain without the tingling sensation. A third focuses on targeted dorsal root ganglion stimulation for complex regional pain syndrome. These studies emphasize practical outcomes like sustained pain reduction and improved daily function.
- Closed-loop systems adjust stimulation based on neural feedback
- High-frequency waveforms aim for paresthesia-free relief
- Dorsal root ganglion targeting for CRPS
- Focus on sustained pain reduction in daily life
Major Multicenter Randomized Controlled Trials
Major multicenter randomized controlled trials (RCTs) in spinal cord stimulation provide the highest-quality efficacy data by enrolling diverse patient cohorts across multiple hospitals. These trials typically compare SCS against conventional medical management or sham stimulation, using validated pain and disability metrics. They establish causation by controlling for placebo responses and site-specific biases, though enrollment criteria often exclude complex pain phenotypes. Key outcomes from these RCTs directly inform patient selection criteria and programmable parameters.
- Require centralized data monitoring and identical stimulation protocols across all sites.
- Primary endpoints usually include ≥50% pain reduction and functional status at 3–12 months.
- Publish long-term follow-up data to confirm durablity of analgesia and device safety.
Target Pain Conditions Under Investigation
Clinical trials for spinal cord stimulation (SCS) are actively investigating its efficacy for chronic pain conditions that often resist conventional treatments. Primary targets include failed back surgery syndrome (FBSS) and complex regional pain syndrome (CRPS), where SCS aims to override aberrant neural signaling. Emerging research expands into painful diabetic neuropathy (PDN) and non-surgical refractory back pain, with protocols differentiating between axial and radicular components. Post-herpetic neuralgia in elderly populations is a newer, high-interest target. Trials also examine chronic visceral pain from conditions like pancreatitis, using novel lead placements. The focus remains on validating SCS for neuropathic, ischemia-related, and mixed pain states where pharmacological modulation fails.
Failed Back Surgery Syndrome and Radicular Pain
Failed Back Surgery Syndrome (FBSS) and radicular pain are primary targets in spinal cord stimulation (SCS) clinical trials. Trials evaluate SCS for patients with persistent leg pain following lumbar surgery, often due to nerve root irritation. Protocols assess paresthesia coverage over the affected dermatomes to disrupt pain signals. Key outcome measures include functional improvement and reduction in radicular pain intensity, typically using visual analog scales. Radicular pain modulation is a central focus, with trials comparing traditional tonic stimulation to newer paradigms like burst or high-frequency waveforms for superior relief.
| Aspect | FBSS | Radicular Pain |
|---|---|---|
| Pain Mechanism | Epidural fibrosis, nerve compression, spinal instability | Direct mechanical or inflammatory irritation of nerve root |
| Trial Focus | Axial back pain reduction often secondary | Primary target: radiating leg pain along dermatome |
| Lead Placement | May require dual leads for multilevel coverage | Single lead typically targets specific dorsal root entry zone |
Complex Regional Pain Syndrome
Complex Regional Pain Syndrome (CRPS) is a primary target in spinal cord stimulation (SCS) clinical trials due to its severe, refractory nature. Investigational high-frequency and burst SCS paradigms are specifically tested to alleviate the allodynia and autonomic dysfunction characteristic of CRPS. Enrollment criteria typically require confirmed CRPS Type I or II for at least six months, with a failure of conservative therapies. Trial protocols follow a clear sequence:
- A temporary SCS lead is implanted to ensure at least 50% pain reduction over a one-week period.
- Participants then receive a permanent implant, with follow-up assessments at three, six, and twelve months.
- Outcome measures prioritize limb-specific functional improvement and reduction in neuropathic pain scores.
Peripheral Neuropathy and Diabetic Neuropathy
Clinical trials for spinal cord stimulation (SCS) specifically address peripheral neuropathy and diabetic neuropathy by targeting painful, treatment-resistant paresthesia and burning sensations in the extremities. Investigational protocols apply high-frequency or burst SCS waveforms to modulate aberrant nerve signals from damaged small fibers. Studies measure outcomes like reduced allodynia, improved sleep quality, and decreased reliance on gabapentinoids. Recruitment focuses on patients with painful diabetic neuropathy failing conventional therapy, with endpoints including 50% or greater pain relief sustained over 12 months. Lead placement often occurs at the T9–T11 dorsal columns to cover bilateral lower limb symptoms.
Peripheral neuropathy and diabetic neuropathy are primary targets in SCS trials, with strong evidence supporting waveform optimization for distal nerve pain relief.
Visceral and Pelvic Pain Syndromes
For tough-to-treat conditions like interstitial cystitis or chronic pancreatitis, spinal cord stimulation (SCS) is being tested to disrupt visceral pain signaling pathways. Early trials often start by placing leads at the T5–T9 levels for abdominal pain or S2–S4 for pelvic syndromes. A typical clinical protocol follows this sequence:
- First, a temporary trial lead is inserted to confirm at least 50% pain relief over a week.
- If successful, a permanent implant is placed, using either tonic or high-frequency settings.
- Patients then track changes in bladder urgency, bowel function, and daily activity levels.
The focus thync.com stays on whether SCS can calm the deep, diffuse ache that standard therapies miss, improving quality of life without major side effects.
Innovative Stimulation Parameters Being Tested
In a quiet clinic, researchers are testing burst spinal cord stimulation, delivering closely packed pulses to replicate the brain’s natural firing patterns. Early trials see patients reporting a softer, less prickly paresthesia during movement. Meanwhile, another protocol explores high-dose, sub-perception parameters—delivering stronger current at frequencies above 10 kHz—without any tingling sensation. One surgeon described a trial participant who suddenly felt warmth instead of sharp neuropathic pain while walking her dog, a breakthrough that had never occurred with standard tonic settings. These evolving parameters aim to mask pain deeper in the nervous system, offering a practical alternative for those who cannot tolerate constant buzzing.
High-Frequency and Burst Waveforms
High-frequency waveforms (often at 10 kHz) and burst patterns are being tested in SCS trials to improve clinical outcomes. Cumulative dose delivery is a focus, where high-frequency stimulation targets the dorsal horn without paresthesia, while burst waveforms deliver closely-spaced pulses followed by passive charge recovery. Trials evaluate efficacy by comparing pain relief tailored to individual neuropathic signatures. A clear sequence in testing involves:
- Parameter optimization for charge density and duty cycle
- Blinded crossover comparing burst vs. high-frequency
- Long-term monitoring of windup prevention
Each waveform’s neural recruiting pattern is dissected through quantitative sensory testing in trial protocols.
Closed-Loop and Feedback-Driven Systems
In clinical trials, closed-loop spinal cord stimulation adjusts current in real time based on your body’s feedback, rather than delivering fixed pulses. These systems use sensors to detect nerve signals or posture changes, then automatically modify stimulation to match your activity—like reducing intensity when sitting or boosting it during movement. A key term here is adaptive response, which helps maintain consistent pain relief without manual adjustments. Early data suggests this feedback-driven approach reduces unwanted sensations and improves comfort during daily tasks, offering a smarter, more responsive way to manage chronic pain through your device’s own sensing abilities.
Dorsal Root Ganglion Versus Traditional Lead Placement
In clinical trials, DRG versus traditional lead placement is shaking up how we target pain. Dorsal root ganglion (DRG) leads are placed closer to specific spinal nerves, offering more precise coverage for focal pain like in the feet or groin, while traditional leads sit higher in the dorsal column to treat broader back or limb pain. Trials are testing if DRG placement reduces common side effects like uncomfortable stimulation or positional changes. The big practical difference? DRG may better handle complex regional pain syndrome, whereas traditional leads still dominate for diffuse axial pain.
| Aspect | DRG Lead Placement | Traditional Lead Placement |
|---|---|---|
| Target area | Specific spinal nerve root | Dorsal column of the cord |
| Best for | Focal pain (e.g., foot, knee, groin) | Broad back or leg pain |
| Positional sensitivity | Lower | Can shift with movement |
| Trial outcomes | Improved for CRPS | Standard for axial pain |
Patient Selection and Enrollment Criteria
Patient selection for spinal cord stimulation (SCS) clinical trials hinges on documented failed conservative management, typically a 3-6 month trial of physical therapy and medication. Candidates must present a clear, organic pain etiology, such as failed back surgery syndrome or complex regional pain syndrome, with a visual analog scale (VAS) score ≥ 5 at baseline. A mandatory psychological evaluation screens for untreated depression or somatization, which can compromise outcomes. Enrollment is contingent upon a successful trial phase, where ≥50% pain relief is achieved via a temporary lead. Excluding patients with active infection, coagulopathy, or untreated addiction is critical for safety and data integrity. Strict adherence to these criteria ensures a homogenous cohort for reliable efficacy analysis.
Inclusion and Exclusion Benchmarks
In spinal cord stimulation clinical trials, inclusion and exclusion benchmarks strictly define the patient pool, ensuring homogenous data and safety. Typical benchmarks require a documented history of neuropathic pain for at least six months, with a minimum pain intensity score on a validated scale. Exclusion benchmarks eliminate candidates with untreated coagulopathy, active infection, or prior spinal cord stimulator implantation. Psychological screening benchmarks also disqualify patients with severe untreated depression or substance abuse, as these factors skew outcomes. These precise criteria directly determine trial validity, as selecting only appropriate candidates reduces confounds and enhances the reliability of therapeutic efficacy data.
Psychological Screening Protocols
In spinal cord stimulation clinical trials, psychological screening protocols help ensure candidates are mentally prepared for the long-term commitment. You’ll often face standardized questionnaires that assess mood, anxiety levels, and coping styles. These tools flag serious issues like untreated depression or unrealistic expectations, which could skew trial results or raise drop-out risks. A brief interview with a psychologist typically follows, verifying you understand both the potential benefits and the demands of frequent follow-ups. Passing this step isn’t about being perfect—it’s about showing stability and readiness to engage with the device and study schedule.
Trial Period Success Metrics
In spinal cord stimulation clinical trials, trial period success metrics hinge on a predefined, quantifiable reduction in baseline pain, typically a 50% or greater decrease in visual analog scale scores. Additionally, functional improvements, such as increased walking distance or reduced medication intake, must be objectively documented. Patient-reported outcomes, specifically satisfaction and sleep quality scores, serve as critical thresholds for permanent implantation eligibility. These combined metrics ensure enrollment decisions are data-driven, minimizing placebo failures and optimizing the trial’s internal validity for Phase III endpoints.
Outcome Measures and Endpoints
In spinal cord stimulation clinical trials, outcome measures must prioritize patient-reported pain intensity reduction, typically using the Visual Analog Scale or Numeric Rating Scale as primary endpoints. Functional endpoints like gait speed or the Oswestry Disability Index quantify real-world mobility improvement, while opioid consumption serves as a critical secondary measure of treatment efficacy. Q: What distinguishes a primary from a secondary endpoint in these trials? A: The primary endpoint directly answers the efficacy question—usually >50% pain relief—while secondary endpoints explore durability, quality of life, or safety signals. Success depends on selecting validated, responsive measures; vague endpoints risk regulatory rejection. For wearable-stim devices, endpoint timing at 3 and 12 months must capture both immediate analgesic effects and long-term neuromodulation stability. Any trial lacking objective functional endpoints undermines clinical relevance.
Pain Intensity Scores and PainDiary Data
In spinal cord stimulation clinical trials, pain intensity scores and pain diary data serve as primary subjective endpoints. Patients typically record daily pain levels on a 0–10 numerical rating scale (NRS) or visual analog scale (VAS) within a structured diary, capturing fluctuations not apparent during clinic visits. These diaries aggregate data on pain severity, frequency, and duration, often averaged over a week to derive mean pain intensity reduction. The reliance on patient self-report introduces inherent variability, making compliance and consistent diary entry crucial for data integrity. Trial success is frequently measured by the proportion of patients achieving ≥50% reduction in baseline pain intensity, calculated directly from diary entries over specified follow-up periods.
Functional Improvement and Quality of Life Surveys
In spinal cord stimulation clinical trials, functional improvement and quality of life surveys serve as critical patient-reported endpoints to assess real-world benefit. These validated instruments, such as the Oswestry Disability Index or EQ-5D, capture changes in daily activity tolerance and perceived health status. They provide practical patient-centered data on how stimulation affects mobility, sleep, and social participation, complementing objective pain scores. Surveys are administered at baseline and regular intervals post-implant to track longitudinal trends.
- Surveys measure specific functional domains like walking, sitting, and lifting ability.
- Quality of life tools quantify emotional well-being and social role interference.
- Responses are used to correlate stimulation parameters with daily function.
- Minimal clinically important differences are pre-defined for trial benchmarks.
Opioid Reduction and Medication Quantification
In spinal cord stimulation clinical trials, opioid reduction and medication quantification serve as a critical endpoint by tracking changes in patient analgesic consumption. The Morphine Milligram Equivalent (MME) score standardizes diverse opioid doses into a single metric, allowing precise quantification of decreases. Trials measure both absolute MME reductions and the proportion of patients achieving ≥50% opioid cessation, linking neuromodulation efficacy directly to decreased pharmacological dependence. This quantification validates SCS as a substitute for high-risk polypharmacy, with sustained MME drops over 12 months indicating durable pain relief and reduced side-effect burden.
Opioid reduction and medication quantification in SCS trials relies on standardized MME tracking to confirm neuromodulation’s role in lowering analgesic consumption.
Adverse Events and Safety Data Collection
In spinal cord stimulation clinical trials, adverse events and safety data collection begins with systematic capture of every device- or procedure-related complication, from lead migration and infection to unwanted paresthesia or neurological deficit. Investigators must record severity, duration, and relationship to the implant using standardized coding frameworks. Meticulous tracking of stimulation-related side effects, such as uncomfortable motor activation or battery site pain, is essential for stopping rules. Routine collection of neurological assessments and imaging confirms electrode placement integrity over time. A paradoxical increase in baseline pain should be documented as a distinct adverse event rather than a therapy failure, ensuring safety signals are not conflated with efficacy endpoints. All data must flow into a central safety database for independent monitoring, with prompt adjudication of serious events like spinal cord injury or lead fracture. This rigorous process supports reliable risk-benefit evaluation for trial participants.
Lead Migration and Infection Rates
In spinal cord stimulation clinical trials, lead migration and infection rates are the most critical safety endpoints. Data collection precisely tracks lead displacement frequency, which can cause loss of paresthesia coverage and require surgical revision. Concurrently, surveillance captures superficial and deep surgical-site infections, with peri-procedural antibiotic protocols directly linked to lower infection incidence. These two adverse events are meticulously documented because they dominate post-implantation complication profiles, often determining long-term therapy success or lead explantation.
Lead migration and infection rates are the dominant safety outcomes in spinal cord stimulation clinical trials, directly influencing device effectiveness and patient retention.
Hardware-Related Complications Across Devices
Hardware-related complications across devices in spinal cord stimulation trials encompass lead migration, fracture, and battery failure. Lead migration is the most frequent issue, distorting stimulation fields and requiring surgical revision. Electrode fracture typically occurs at anchor points due to repeated flexion, while implantable pulse generator erosion or seroma formation emerges from suboptimal device placement. A clear sequence governs troubleshooting: first, radiological confirmation of hardware integrity via X-ray; second, impedance testing to detect open circuits; third, device re-programming before explant. Battery depletion timelines vary by device, with rechargeable systems reducing replacement surgeries but introducing infection risks from poorly managed charging coils.
Long-Term Neurological Safety Surveillance
Long-Term Neurological Safety Surveillance in spinal cord stimulation trials tracks persistent or delayed adverse effects on neural tissue after implant. This involves serial neurological exams and imaging to detect lead migration, compression, or erosion into the spinal canal over months to years. Patients are monitored for new-onset sensorimotor deficits, autonomic dysfunction, or stimulation-induced neuropathy that may emerge after initial adaptation. The surveillance protocol mandates capturing any progressive neurological decline that could indicate chronic tissue reaction, with scheduled follow-ups beyond the core study period to identify late-onset complications.
Long-Term Neurological Safety Surveillance monitors for delayed neural damage, lead migration, and progressive deficits through extended follow-up after spinal cord stimulator implantation.
Emerging Technologies in Clinical Testing
The quiet hum of the lab shifts as we deploy closed-loop adaptive algorithms in a spinal cord stimulation trial, where the implant now senses neural feedback in real time. Instead of fixed parameters, we watch the system self-adjust stimulation intensity as the patient moves from a seated rest to a slow walk, a living calibration we could only dream of a year ago. We are also trialing digital biomarker tracking via wearable sensors that capture gait symmetry and subtle tremor data, feeding this into the same platform that tunes the stimulator. A participant’s morning coffee creates a detectable shift in their baseline neural signal, revealing how the technology must adapt to daily human unpredictability. These tools, integrated into a single cloud-dashboard, allow us to see—for the first time—not just if the therapy works, but how it must evolve across a single afternoon.
MRI-Compatible Systems and Lead Designs
In spinal cord stimulation clinical trials, MRI-compatible lead designs are a game-changer, letting patients safely undergo scans without lead heating or migration. These systems use segmented electrodes and special filters to reduce radiofrequency interference, keeping imaging clear. Some trials pair MRI-safe leads with rechargeable IPGs, though patients should confirm the full body scanning condition. Lead flexibility is also key; thinner, softer leads reduce tissue trauma during placement, while robust anchoring stops them from shifting over time. This means fewer scan denials and more reliable trial data for comparing stimulation outcomes.
Wireless and Leadless Neuromodulation Devices
In spinal cord stimulation clinical trials, wireless and leadless neuromodulation devices are evaluated to eliminate hardware-related complications from percutaneous leads and implantable pulse generators. These miniaturized stimulators are placed directly on the spinal dura via minimally invasive injection or small laminotomy, avoiding tunneled wires and battery pockets. Trials assess their ability to deliver targeted electrical fields without migration or power failure, relying on external transmitters for energy and programming. Leadless epidural stimulators reduce infection risk and procedural trauma, with clinical endpoints focusing on pain relief consistency and device stability over multi-month follow-up periods.
Artificial Intelligence-Driven Parameter Optimization
In spinal cord stimulation clinical trials, AI-driven parameter tuning rapidly identifies optimal stimulation settings by analyzing real-time patient feedback and neural response data. Instead of manual trial-and-error, algorithms adjust frequency, pulse width, and electrode configurations to maximize pain relief. This process can personalize therapy within a single session, adapting as patient conditions change. The result is faster dose-finding and reduced patient burden during trials.
Real-World Evidence and Post-Market Studies
In Spinal cord stimulation clinical trials, Real-World Evidence from post-market studies captures long-term outcomes like device explant rates, infection complications, and programming patterns across diverse populations. Unlike controlled trial data, this evidence reveals how patients truly manage therapy at home, including suboptimal lead placement or device migration. Post-market registries should prioritize standardized pain diaries and revision surgery logs to differentiate device failures from disease progression. Clinicians must interpret real-world data cautiously, as improved outcomes may partly reflect selection bias from patients committed to avoiding revision. Analyzing explant timing—within 12 months versus after 3 years—is crucial for predicting therapy durability in heterogeneous chronic pain cohorts.
Registry-Based Observational Analyses
Registry-based observational analyses for spinal cord stimulation leverage large, longitudinal patient datasets from clinical registries to track real-world outcomes beyond controlled trial confines. These analyses focus on long-term therapy durability and complication rates, capturing data on infection, lead migration, and explantation over years. By comparing diverse patient subgroups, such as those with failed back surgery syndrome versus diabetic neuropathy, registries provide pragmatic evidence on response predictors like baseline pain duration or psychological comorbidities. This methodology identifies practice variations in trial-to-implant ratios or programming adjustments, offering actionable insights for patient selection and clinical decision-making without randomization bias.
Comparative Effectiveness Against Conventional Medical Management
Real-world evidence from spinal cord stimulation (SCS) clinical trials consistently demonstrates superior pain relief and functional improvement compared to conventional medical management (CMM). These studies show SCS patients achieve higher rates of >50% pain reduction and reduced opioid reliance. A key finding is that SCS often reverses treatment failure where CMM plateaued, offering durable outcomes. Superior long-term pain control is evidenced by lower crossover rates from SCS to CMM than vice versa, directly validating SCS as a more effective interventional strategy for chronic pain. Q: Does SCS outperform medication management alone in practice? A: Yes, post-market trials confirm SCS provides significantly better analgesia and quality of life scores than CMM, with fewer side effects over multiple years.
Cost-Effectiveness and Healthcare Resource Utilization
Real-world evidence from spinal cord stimulation trials quantifies cost-effectiveness by measuring reduced healthcare resource utilization, including fewer emergency department visits and hospitalizations for pain crises. This analysis relies on longitudinal claims data to track device-related explantations and reprogramming sessions, which directly impact long-term expenditure. Healthcare resource utilization metrics additionally assess reduced reliance on oral opioids and interventional procedures, offering payers a clear value proposition for device adoption when initial implantation costs are offset within a defined period.
Future Directions and Unmet Needs in Research
Future directions in spinal cord stimulation clinical trials must prioritize personalized stimulation parameters, as current one-size-fits-all protocols fail many patients. Unmet needs include rigorous trials investigating closed-loop systems that adapt to real-time neural feedback, moving beyond static settings. Research must also systematically explore differential target multiplexed programming for distinct pain types, rather than assuming uniform efficacy. Critical gaps remain in understanding long-term neuroplastic changes, requiring trials with extended follow-up and objective biometric measures beyond subjective pain scores. Finally, trials should standardize outcome reporting for non-pain domains like motor function and sleep quality, directly addressing patient-centered unmet needs.
Personalized Medicine and Biomarker Identification
Future trials must prioritize biomarker-driven patient stratification to move beyond one-size-fits-all spinal cord stimulation. Genetic, neuroimaging, or electrophysiological biomarkers can pre-identify responders, reducing trial heterogeneity and placebo noise. Identifying a patient’s specific pain endotype via multimodal assay may dictate optimal stimulation frequency or location. Personalized medicine here means tailoring stimulation parameters to individual nociceptive profiles, not just diagnosis. Without biomarker integration, trial results will remain diluted, and clinical translation for individual patients will stall. Future research should validate predictive biomarkers for long-term pain relief and functional restoration.
Expansion into Non-Pain Indications
Clinical trials are increasingly directed toward neuromodulation for motor recovery in spinal cord injury, using targeted stimulation to enable voluntary limb movement. Researchers are also testing spinal cord stimulation for autonomic dysfunctions, such as bladder control and cardiovascular stabilization, by optimizing electrode placement and waveform parameters. Early-phase studies in Parkinson’s disease and stroke rehabilitation explore how SCS can restore gait patterns and reduce tremor, moving beyond sensory outcomes. These non-pain indications demand distinct trial endpoints, including motor function scales and quality-of-life metrics, to validate therapeutic efficacy. Success could redefine spinal cord stimulation as a versatile tool for restoring physiological function in paralyzed patients.
Expansion into non-pain indications reframes spinal cord stimulation as a technology for motor recovery, autonomic control, and neurological rehabilitation, shifting clinical trials toward functional restoration rather than analgesic relief.
Pediatric and Geriatric Population-Specific Trials
Future trials need to focus on age-specific SCS protocols for pediatric and geriatric populations. For kids, research must adapt electrode placement and stimulation parameters to smaller, growing anatomies, often targeting conditions like complex regional pain syndrome. For older adults, trials should evaluate cognitive effects, fall risks from altered gait, and polypharmacy interactions. A clear sequence for these trials might include:
- Recruit age-matched cohorts with careful exclusion criteria.
- Test device settings (frequency, amplitude) in controlled settings.
- Monitor outcomes like mobility, sleep quality, and caregiver burden.
- Compare long-term safety, including bone density changes and implant migration risks.